Cardiff Oncology Appoints New CEO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 27 2026
0mins
Should l Buy CRDF?
Cardiff Oncology announced a leadership transition. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their respective roles. As part of this transition, Brigitte Lindsay has been promoted to the role of Chief Accounting Officer. She has been with the Company for more than 14 years and was most recently the Senior Vice President of Finance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRDF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRDF
Wall Street analysts forecast CRDF stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.730
Low
10.00
Averages
13.67
High
19.00
Current: 1.730
Low
10.00
Averages
13.67
High
19.00
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardiff Oncology Reports 2025 Financial Results and Business Update
- Financial Overview: Cardiff Oncology reported royalty revenues of $0.6 million for 2025, a slight decrease from $0.7 million in 2024, while total operating expenses remained stable at $49.6 million, resulting in a net loss of $45.9 million or $0.69 per share, which is an improvement over the previous year's loss of $45.5 million or $0.95 per share, indicating better financial management.
- Clinical Trial Progress: The Phase 2 CRDF-004 trial for RAS-mutated metastatic colorectal cancer showed that the 30 mg Onvansertib combined with FOLFIRI/bev achieved a 72.2% objective response rate, significantly higher than the 43.2% in standard care arms, laying a solid foundation for advancing into a registrational program, with detailed data and regulatory plans expected in the first half of 2026.
- Cash Position: As of 2025, Cardiff's cash, cash equivalents, and short-term investments totaled $58.3 million, which is expected to fund operations into the first quarter of 2027, demonstrating strong financial management and providing a buffer for ongoing research and development.
- Leadership Changes: In January 2026, Cardiff announced executive changes with Mani Mohindru appointed as interim CEO and Brigitte Lindsay promoted to Chief Accounting Officer, reflecting the company's strategic restructuring to support late-stage development while actively searching for a permanent CEO and CFO to enhance management stability.
See More
Cardiff Oncology Reports FY EPS Beat Amid Revenue Decline
- Earnings Highlights: Cardiff Oncology reported a FY GAAP EPS of -$0.69, beating expectations by $0.08, indicating some financial resilience despite still being in negative territory.
- Revenue Trends: The company generated $0.59M in revenue, a 13.2% year-over-year decline, yet it surpassed market expectations by $0.14M, suggesting a stable customer base amid challenges.
- Leadership Changes: Following the earnings release, Cardiff Oncology experienced a leadership shakeup, which could impact the company's strategic direction and investor confidence, necessitating close monitoring of management stability.
- Future Outlook: Despite current challenges, the market remains cautiously optimistic about Cardiff Oncology's future performance, particularly with the upcoming Phase II data update for Onvansertib in RAS-mutated mCRC, which may present new growth opportunities.
See More
Cardiff Oncology Management Shakeup and Trial Update
- Management Changes: Cardiff Oncology announced the resignation of CEO Mark Erlander and CFO James Levine, with board member Mani Mohindru appointed as interim CEO, reflecting a focus on execution and clinical advancement that may impact investor confidence negatively.
- Clinical Trial Data Update: In the CRDF-004 Phase 2 trial for RAS-mutated metastatic colorectal cancer, the 30 mg dose group achieved a confirmed objective response rate of 72.2%, significantly higher than the 43.2% in the standard care group, indicating the potential efficacy of the new drug and possibly driving future registrational trials.
- Registrational Trial Plans: Based on clinical data, Cardiff Oncology plans to initiate a registrational trial later this year comparing onvansertib with standard care for 1L patients, which, if successful, could help expand market share.
- Analyst Perspective: William Blair lowered the probability of success from 50% to 45%, suggesting that the abrupt management changes and narrow focus on onvansertib may limit market opportunities, leading to a 31.9% drop in stock price to $2, close to the 52-week low.
See More
Cardiff Oncology Shares Plunge 35% Following CEO and CFO Resignations
- Executive Departures: Cardiff Oncology's CEO Mark Erlander and CFO James Levine resigned, causing shares to plummet approximately 35% to a new 52-week low, indicating market concerns over leadership instability.
- Interim Leadership: The board appointed veteran biotech executive Mani Mohindru as interim CEO to replace Erlander, ensuring operational continuity during the executive transition period.
- Financial Stability: Brigitte Lindsay was promoted to Chief Accounting Officer to maintain the finance department's functionality, reflecting the company's commitment to financial management amid leadership changes.
- Clinical Trial Update: Cardiff announced plans to further test a 30 mg dose of its lead drug onvansertib in combination with FOLFIRI/bevacizumab, with a registrational trial expected to begin later this year pending FDA design confirmation, aiming to provide new treatment options for RAS-mutated metastatic colorectal cancer.
See More
Oncolytics Biotech Secures FDA Approval for First Pancreatic Cancer Immunotherapy
- Regulatory Milestone: Oncolytics Biotech has secured FDA approval for its pivotal Phase 3 trial design for pelareorep in pancreatic cancer, marking a significant step in a field lacking existing immunotherapy options, potentially providing new treatment avenues for patients.
- Clinical Trial Design: The trial will compare standard chemotherapy with pelareorep, with overall survival as the primary endpoint, and success could solidify Oncolytics' position in a competitive market, enhancing its market standing.
- Market Potential: Analysts project the global immuno-oncology market will grow at a CAGR of 15.7% to reach $416.28 billion by 2034, positioning Oncolytics favorably within this rapidly expanding sector.
- Strategic Development: Oncolytics has also established a Gastrointestinal Scientific Advisory Board to advance pelareorep beyond pancreatic cancer, further expanding its market potential and demonstrating the company's strategic focus on multiple tumor types.
See More
Cardiff Unveils Phase 1 Results of Onvensertib for Chronic Myelomonocytic Leukemia at ASH 2025
Clinical Trial Results: Cardiff Oncology presented new data from a Phase 1 trial of onvansertib, a PLK1 inhibitor, for treating relapsed/refractory chronic myelomonocytic leukemia (CMML) at the ASH Annual Meeting, showing preliminary efficacy in about 40% of patients.
Drug Tolerability: Onvansertib was well-tolerated as a monotherapy, with manageable treatment-emergent adverse events reported among the nine enrolled patients.
Future Development Plans: Although Cardiff Oncology does not plan to further develop onvansertib for CMML, the results support its potential in treating various hematologic and solid tumors.
Stock Performance: Following the announcement, Cardiff Oncology's stock rose by 10.90% to $2.34, with a slight increase in after-hours trading, reflecting positive investor sentiment.
See More
Cardiff Oncology Reports 2025 Financial Results and Business Update
- Financial Overview: Cardiff Oncology reported royalty revenues of $0.6 million for 2025, a slight decrease from $0.7 million in 2024, while total operating expenses remained stable at $49.6 million, resulting in a net loss of $45.9 million or $0.69 per share, which is an improvement over the previous year's loss of $45.5 million or $0.95 per share, indicating better financial management.
- Clinical Trial Progress: The Phase 2 CRDF-004 trial for RAS-mutated metastatic colorectal cancer showed that the 30 mg Onvansertib combined with FOLFIRI/bev achieved a 72.2% objective response rate, significantly higher than the 43.2% in standard care arms, laying a solid foundation for advancing into a registrational program, with detailed data and regulatory plans expected in the first half of 2026.
- Cash Position: As of 2025, Cardiff's cash, cash equivalents, and short-term investments totaled $58.3 million, which is expected to fund operations into the first quarter of 2027, demonstrating strong financial management and providing a buffer for ongoing research and development.
- Leadership Changes: In January 2026, Cardiff announced executive changes with Mani Mohindru appointed as interim CEO and Brigitte Lindsay promoted to Chief Accounting Officer, reflecting the company's strategic restructuring to support late-stage development while actively searching for a permanent CEO and CFO to enhance management stability.
See More
Cardiff Oncology Reports FY EPS Beat Amid Revenue Decline
- Earnings Highlights: Cardiff Oncology reported a FY GAAP EPS of -$0.69, beating expectations by $0.08, indicating some financial resilience despite still being in negative territory.
- Revenue Trends: The company generated $0.59M in revenue, a 13.2% year-over-year decline, yet it surpassed market expectations by $0.14M, suggesting a stable customer base amid challenges.
- Leadership Changes: Following the earnings release, Cardiff Oncology experienced a leadership shakeup, which could impact the company's strategic direction and investor confidence, necessitating close monitoring of management stability.
- Future Outlook: Despite current challenges, the market remains cautiously optimistic about Cardiff Oncology's future performance, particularly with the upcoming Phase II data update for Onvansertib in RAS-mutated mCRC, which may present new growth opportunities.
See More
Cardiff Oncology Management Shakeup and Trial Update
- Management Changes: Cardiff Oncology announced the resignation of CEO Mark Erlander and CFO James Levine, with board member Mani Mohindru appointed as interim CEO, reflecting a focus on execution and clinical advancement that may impact investor confidence negatively.
- Clinical Trial Data Update: In the CRDF-004 Phase 2 trial for RAS-mutated metastatic colorectal cancer, the 30 mg dose group achieved a confirmed objective response rate of 72.2%, significantly higher than the 43.2% in the standard care group, indicating the potential efficacy of the new drug and possibly driving future registrational trials.
- Registrational Trial Plans: Based on clinical data, Cardiff Oncology plans to initiate a registrational trial later this year comparing onvansertib with standard care for 1L patients, which, if successful, could help expand market share.
- Analyst Perspective: William Blair lowered the probability of success from 50% to 45%, suggesting that the abrupt management changes and narrow focus on onvansertib may limit market opportunities, leading to a 31.9% drop in stock price to $2, close to the 52-week low.
See More
Cardiff Oncology Shares Plunge 35% Following CEO and CFO Resignations
- Executive Departures: Cardiff Oncology's CEO Mark Erlander and CFO James Levine resigned, causing shares to plummet approximately 35% to a new 52-week low, indicating market concerns over leadership instability.
- Interim Leadership: The board appointed veteran biotech executive Mani Mohindru as interim CEO to replace Erlander, ensuring operational continuity during the executive transition period.
- Financial Stability: Brigitte Lindsay was promoted to Chief Accounting Officer to maintain the finance department's functionality, reflecting the company's commitment to financial management amid leadership changes.
- Clinical Trial Update: Cardiff announced plans to further test a 30 mg dose of its lead drug onvansertib in combination with FOLFIRI/bevacizumab, with a registrational trial expected to begin later this year pending FDA design confirmation, aiming to provide new treatment options for RAS-mutated metastatic colorectal cancer.
See More
Oncolytics Biotech Secures FDA Approval for First Pancreatic Cancer Immunotherapy
- Regulatory Milestone: Oncolytics Biotech has secured FDA approval for its pivotal Phase 3 trial design for pelareorep in pancreatic cancer, marking a significant step in a field lacking existing immunotherapy options, potentially providing new treatment avenues for patients.
- Clinical Trial Design: The trial will compare standard chemotherapy with pelareorep, with overall survival as the primary endpoint, and success could solidify Oncolytics' position in a competitive market, enhancing its market standing.
- Market Potential: Analysts project the global immuno-oncology market will grow at a CAGR of 15.7% to reach $416.28 billion by 2034, positioning Oncolytics favorably within this rapidly expanding sector.
- Strategic Development: Oncolytics has also established a Gastrointestinal Scientific Advisory Board to advance pelareorep beyond pancreatic cancer, further expanding its market potential and demonstrating the company's strategic focus on multiple tumor types.
See More
Cardiff Unveils Phase 1 Results of Onvensertib for Chronic Myelomonocytic Leukemia at ASH 2025
Clinical Trial Results: Cardiff Oncology presented new data from a Phase 1 trial of onvansertib, a PLK1 inhibitor, for treating relapsed/refractory chronic myelomonocytic leukemia (CMML) at the ASH Annual Meeting, showing preliminary efficacy in about 40% of patients.
Drug Tolerability: Onvansertib was well-tolerated as a monotherapy, with manageable treatment-emergent adverse events reported among the nine enrolled patients.
Future Development Plans: Although Cardiff Oncology does not plan to further develop onvansertib for CMML, the results support its potential in treating various hematologic and solid tumors.
Stock Performance: Following the announcement, Cardiff Oncology's stock rose by 10.90% to $2.34, with a slight increase in after-hours trading, reflecting positive investor sentiment.
See More
